Cargando…
Dimebon Slows Progression of Proteinopathy in γ-Synuclein Transgenic Mice
Intermediates and final products of protein aggregation play crucial role in the development of degenerative changes in a number of neurological diseases. Pathological protein aggregation is currently regarded as one of the most promising therapeutic targets for treatment of these diseases. Transgen...
Autores principales: | Bachurin, Sergey O., Shelkovnikova, Tatyana A., Ustyugov, Alexey A., Peters, Owen, Khritankova, Ina, Afanasieva, Marina A., Tarasova, Tatyana V., Alentov, Igor I., Buchman, Vladimir L., Ninkina, Natalia N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351599/ https://www.ncbi.nlm.nih.gov/pubmed/22179976 http://dx.doi.org/10.1007/s12640-011-9299-y |
Ejemplares similares
-
Dimebon Does Not Ameliorate Pathological Changes Caused by Expression of Truncated (1–120) Human Alpha-Synuclein in Dopaminergic Neurons of Transgenic Mice
por: Shelkovnikova, Tatyana A., et al.
Publicado: (2011) -
A bioisostere of Dimebon/Latrepirdine delays the onset and slows the progression of pathology in FUS transgenic mice
por: Chaprov, Kirill, et al.
Publicado: (2021) -
A novel resource for studying function and dysfunction of α-synuclein: mouse lines for modulation of endogenous Snca gene expression
por: Ninkina, Natalia, et al.
Publicado: (2015) -
Fused in Sarcoma (FUS) Protein Lacking Nuclear Localization Signal (NLS) and Major RNA Binding Motifs Triggers Proteinopathy and Severe Motor Phenotype in Transgenic Mice
por: Shelkovnikova, Tatyana A., et al.
Publicado: (2013) -
Gamma-Carbolines Derivatives As Promising Agents for the Development of Pathogenic Therapy for Proteinopathy
por: Skvortsova, V. I., et al.
Publicado: (2018)